Table 1.
Clinical characteristics of patients studied for circulating T cell phenotypes.
| Clinical features | Control (n=20) |
Hypertension (n=20) |
p value |
|---|---|---|---|
| Female sex (n; %) | 11 (55%) | 11 (55 %) | NS |
| Age (years ± SD) | 52.6 ± 12 | 52.6 ± 11 | NS |
| BMI (kg/m2 ± SD) | 28.2 ± 5.1 | 28.9 ± 5.1 | NS |
| Blood pressure characteristics | |||
| Hypertension (%) | 0% | 100% | <0.05 |
| Office blood pressure | 126±13/83±8 | 150±19/90±11 | <0.05 |
| 24h ABPM (systolic mmHg ± SD) | 120±13 | 143±18 | <0.05 |
| 24h ABPM (diastolic mmHg ± SD) | 75±5 | 85±9 | <0.05 |
| Renin (after supine position) | 10.8±6 | 18±9 | <0.05 |
| Aldosterone (after supine position) | 126±30 | 230±150 | <0.05 |
| Target organ characteristics | |||
| GFR | 74±14 | 78±12 | NS |
| Serum creatinine (µmol/L) | 81±17 | 75 ± 24 | NS |
| LVEDV | 103±26 | 110 ± 28 | NS |
| LVESV | 41±15 | 34 ±11 | NS |
| EF | 65±7 | 65±7 | NS |
| Cardiovascular risk characteristics | |||
| Current Smoking (%) | 2 (10%) | 3 (15%) | NS |
| Ever smoking status (%) | 8 (40%) | 8 (40%) | NS |
| Glucose intolerance/DM | 1 (5%) | 5 (25%) | NS |
| Current blood glucose (mmol/L) | 5.5±0.6 | 6.1±1.5 | NS |
| Total cholesterol (mmol/L) | 5.7±1.0 | 4.9±1.7 | NS |
| Inflammatory/Autoimmune disease | 0 (0%) | 0 (0%) | NS |
| hsCRP level | 0.20±0.18 | 0.16±0.09 | NS |
| WBC (cells/mm3) | 6.3±1.2 | 6.3±1.6 | NS |
| Atherosclerosis and CAD | |||
| Ischemic heart disease (%) | 2 (10%) | 4 (20%) | NS |
| Prior myocardial infarction (%) | 0 (0%) | 3 (15%) | NS |
| Peripheral Arterial Disease (%) | 0 (0%) | 0 (0%) | NS |
| Stroke/TIA | 0 (0%) | 0 (0%) | NS |
| PAD | 0 (0%) | 0 (0%) | NS |
| Medications | |||
| ACE inhibitors (%) | 0 (0%) | 9 (45%) | |
| Angiotensin Receptor Blockers (%) | 0 (0%) | 6 (30%) | |
| Beta – blockers (%) | 0 (0%) | 12 (60%) | |
| Calcium channel blockers (%) | 0 (0%) | 14 (70%) | |
| Alpha – blockers (%) | 0 (0%) | 6 (30%) | |
| Diuretics (%) | 0 (0%) | 9 (45%) | |
| Statins (%) | 1 (5%) | 9 (45%) |